News
Public · Published
Merck's therapy extends survival in hard-to-treat uterine cancer patients
Merck's experimental drug sac-TMT helped advanced endometrial cancer patients live longer than standard chemotherapy in a late-stage trial of 776 patients. The US health regulator accepted it for priority review, with a decision expected by June 2027.
Published:
Updated:
What happened
Merck's experimental drug sac-TMT helped advanced endometrial cancer patients live longer than standard chemotherapy in a late-stage trial of 776 patients. The US health regulator accepted it for priority review, with a decision expected by June 2027.
Confirmed
Global impact / market context
If approved, the drug gives Merck a new option in endometrial cancer, where patients whose disease returns after earlier treatment have limited choices. Priority review shortens the review clock, which means a US sales decision could arrive sooner than usual.
Analyst inference
The trial compared sac-TMT with doctor-chosen chemotherapy, a common late-stage design. Longer survival and longer time before disease worsened support a potential new treatment, though more severe side effects affecting 54% of patients could weigh on how doctors use it.
Analyst inference
What to watch
- Watch the US regulator's decision, expected by June 2027, on whether to approve sac-TMT for advanced endometrial cancer after priority review acceptance. Confirmed
- Merck could seek approval in other countries and tumor types where TROP2, a protein common in endometrial tumors, is present, but no such plans are stated. Proposed
- Doctors may weigh the 32% lower risk of death against severe side effects in 54% of patients, shaping how widely the drug is prescribed if approved. Analyst inference
Evidence
- Original source link unavailable